This thoroughly revised second edition complied in 2 books is an up-to-date overview of the current clinical advances in sarcoma and osteosarcoma. The new edition features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, these essential volumes also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focused approaches for treatment of osteosarcoma metastases, as well as thoughts on the current standard of treatment for patients suffering from these cancers. In the years since the previous edition, there have been numerous new developments in this rapidly changing field; this new edition is both timely and urgently needed. When taken together these companion volumes, Current Clinical (Book 1) and Scientific (Book 2) Advances in Osteosarcoma, are a timely and urgently needed guide for laboratory investigators and clinical oncologists focused in sarcoma.

<p>Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma:  A Historical Perspective

Part 1:  Surgical Considerations and Outcomes.- Limb Salvage and Reconstruction Options in Osteosarcoma.- Advances in the functional assessment of patients with sarcoma
Part II:  Novel Therapeutic Approaches Based on Biology.- Radiopharmaceuticals for Treatment of Osteosarcoma.- HER-2 Targeted Therapy in Osteosarcoma.- Aerosolized Chemotherapy for Osteosarcoma.- The Histone Deacetylase inhibitor Entinostat/Syndax 275 in Osteosarcoma.- Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease.- Using liquid biopsy in the treatment of patient with osteosarcoma
Part III:  Novel Immunotherapeutic Approaches.- Genetically modified T-cell therapy for osteosarcoma: into the roaring 2020's.- Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma.- Natural Killer Cell Immunotherapy for Osteosarcoma.- Nanocapsule delivery of IL-12.- Discovery of cell surface vimentin (CSV) as a sarcoma target and development of CSV-targeted IL-12 immune therapy.- Part IV:  Survivorship and Late Effects.- Editorial Comments on late effects.- Anthracycline-Induced Cardiotoxicity: Causes, mechanisms & prevention.- Exercise and Physical Activity in Patients with Osteosarcoma and Survivors
Index.</p>